◆ mixed
Impact
PhaseCommercial/Compounded Product (not FDA-approved drug)
Time to marketAlready available for dispensing (Q3 2026); revenue expected to begin in the current quarter.
DARE to PLAY sildenafil topical cream Updated Sep 13
What to watch
Watch for Q3 2026 earnings (likely November 2026) for the first DARE to PLAY dispensing and revenue figures, this will be the first real read on commercial traction. Also monitor Nasdaq listing compliance updates and any further dilutive financing, as the company's cash runway extends only into Q4 2026.
Bull case
- Addresses a large, underserved market, female sexual dysfunction has no widely accepted FDA-approved treatment, creating a first-mover opportunity.
- Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $8.33 (over 1,000% implied upside from the ~$0.70 stock price).
- As a compounded product (not an FDA-regulated new drug), DARE to PLAY avoids lengthy clinical trials and can generate revenue quickly once dispensing begins.
Bear case
- Severe financial distress: cash burned from $24.7M to $12.6M in H1 2026, with negative working capital and stockholders' deficit, cash runway extends only into Q4 2026.
- Active Nasdaq delisting risk with a hearing scheduled in late August 2026; stock trades near its 52-week low of $0.69.
- Massive dilution overhang: a ~$6M August 2026 offering at $1.37/share plus warrants for up to 200% additional shares, and an S-1 registration effective September 2026 for further potential share sales.